The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...
The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for ...
Pharmaceutical Technology on MSN
Cell and gene therapy investment strategy pivots as funding dries up
Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.
This study shows that vacancy-engineered MoS₂ nanoflowers drive mitochondrial biogenesis in human mesenchymal stem cells by ...
Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for ...
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...
New Access, Safety Standards, and Field Expertise Explained Coalinga, United States – December 1, 2025 / Conservative Game ...
Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback